Drug news
EU approval for Anoro Ellipta for Chronic Obstructive Pulmonary Disease- GSK/Theravance
GlaxoSmithKline and Theravance, Inc. announced that the European Commission has on 8 May 2014 granted marketing authorisation for Anoro(umeclidinium/vilanterol) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). Anoro is a once-daily combination treatment comprising two bronchodilators, umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single inhaler, the Ellipta. The licensed strength in Europe is UMEC/VI 55mcg / 22mcg.